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Insulin resistance is central to the pathogenesis of type 2 diabetes mellitus. Previous studies have demonstrated that compounds that cause
adipogenesis and improve glucose uptake in 3T3-L1 cells are potential insulin sensitizers. Therefore, we evaluated one such compound, 18F9,
for (1) adipogenesis in human subcutaneous preadipocyte (SQ) cells, (2) glucose uptake in human skeletal muscle myotubes and SQ cells, and
(3) antidiabetic activity in db/db mice. We also investigated its effect on ex vivo glucose uptake in soleus muscle isolated from continuously
treated db/db mice. Gene expression profiling in soleus muscle and epididymal fat of db/db mice was performed to understand its effect on
glucose metabolism, lipid metabolism, and thermogenesis. 18F9 enhanced adipogenesis in SQ cells and increased glucose uptake in SQ and
human skeletal muscle myotubes cells. In db/db mice, 18F9 exhibited dose-dependent reduction in plasma glucose and insulin level.
Interestingly, 18F9 was as efficacious as rosiglitazone but did not cause body weight gain and hepatic adverse effects. In addition, 18F9
demonstrated no change in plasma volume in Wistar rats. Furthermore, it enhanced ex vivo glucose uptake in soleus muscles in these mice,
which substantiates our in vitro findings. Human peroxisome proliferator activated receptor–γ transactivation assay revealed a weak
peroxisome proliferator activated receptor–γ transactivation potential (44% of rosiglitazone at 10 μmol/L) of 18F9. Gene expression profiling
indicated that 18F9 increased insulin sensitivity mainly through a phosphoinositide 3-kinase–dependent mechanism. 18F9 also up-regulated
genes involved in lipid transport and synthesis at par with rosiglitazone. Unlike rosiglitazone, 18F9 elevated the expression of Pdk4. In addition,
18F9 elevated the expression of glycogen synthase and adiponectin significantly higher than rosiglitazone. Taken together, these observations
suggest that 18F9 is a safer and potent insulin sensitizer that demonstrates promising antidiabetic activity and is worth further development.
© 2009 Elsevier Inc. All rights reserved.1. Introduction
Insulin resistance in peripheral tissues, namely, liver,
skeletal muscle, and adipose tissue, plays a pivotal role in the
pathogenesis of type 2 diabetes mellitus. Insulin resistance in
association with hyperglycemia and dyslipidemia is mainly
responsible for the early onset of cardiovascular disorder,⁎ Corresponding author. Tel.: +91 22 3081 8404; fax: +91 22 3081
8411.
E-mail address: kumar.nemmani@piramal.com (K.V.S. Nemmani).
0026-0495/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
doi:10.1016/j.metabol.2009.04.036hypertension, and coronary artery disease [1,2]. Therefore,
amelioration of insulin resistance is an effective way not only
to treat type 2 diabetes mellitus but also to prevent
development of further complication. Among the currently
available pharmacologic agents, thiazolidinediones (TZDs)
are one of the widely used drugs to treat insulin resistance.
However, these agents are associated with adverse effects like
plasma volume expansion, anemia, edema, weight gain, and
hepatic failure [3]. Hence, efforts are being directed toward
the development of insulin sensitizers, which are devoid of
such adverse effects. Recently, a non-TZD compound, 18F9,
has been reported to enhance adipogenesis and increase
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insulin sensitizer.
Adipogenesis of human subcutaneous preadipocytes
(SQs) and insulin-mediated glucose uptake in differentiated
human adipocytes and myotubes have been used to study
insulin sensitizers [5-7]. In the present study, we evaluated
18F9 for its adipogenicity and glucose uptake in human SQ
cells. We also studied its effect on glucose uptake in human
myotubes. Our results demonstrate that 18F9 caused
adipogenesis in human SQ cells along with increased
insulin-mediated glucose uptake in human SQ and human
skeletal muscle myoblasts/myotubes (HSMM) cells. Sub-
sequent to these in vitro findings, we investigated 18F9 for
its antidiabetic activity in diabetic (db/db) mice. 18F9
exhibited reduction in plasma glucose and insulin compar-
able with rosiglitazone. Interestingly, 18F9 did not show
significant body weight gain or hepatic adverse effects. In
addition, a 28-day repeated-dose study in normal Wistar rats
indicated that 18F9 did not cause an increase in plasma
volume or heart weight.
In agreement with the fact that skeletal muscle accounts
for approximately 80% of glucose utilization, we performed
ex vivo–based glucose uptake study in soleus muscle
isolated from continuously treated db/db mice. 18F9
exhibited significant ex vivo insulin sensitization in soleus
muscle, similar to that of rosiglitazone, in addition to its
effect on cultured human adipocytes and myotubes. To
understand its molecular mechanism, we attempted to
elucidate the gene expression profile of 18F9 in diabetic
soleus muscle and epididymal fat. Accordingly, we studied
an array of genes involved in glucose transport and disposal;
lipid transport, synthesis, and oxidation; and thermogenesis.
18F9 preferentially up-regulated key genes involved in
glucose homeostasis, lipid metabolism, and thermogenesis in
soleus muscle in addition to increased adiponectin expres-
sion in epididymal fat. On the basis of the above results, we
conclude that 18F9 appears to be a safe and effective insulin
sensitizer, which improves glucose metabolism, lipid
metabolism, and thermogenesis.2. Materials and methods
2.1. Reagents and chemicals
18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahy-
drothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid;
molecular weight, 399.98) was synthesized at the Piramal
Healthcare, Ennore. Of the 10 000 diverse compounds
library screened by Choi et al [4], 4 compounds—92D8,
99D5, 18F9, and 124D8—exhibited insulin-sensitizing
activity stronger than pioglitazone at 10 μmol/L. According
to Choi et al, 124D8 was the best among the 4 compounds.
However, in preliminary studies in our laboratory, 18F9
exhibited better activity as compared with 124D8; hence, it
was selected for further studies. Rosiglitazone was
synthesized in-house at the Department of Chemistry,Piramal Life Sciences, Mumbai. Human SQ cells, pre-
adipocyte medium (PM-1), differentiation medium (DM2),
adipocyte medium (AM1), and basal medium required for
SQ cells were obtained from Zenbio, Research Triangle
Park, NC. The HSMM cells, skeletal muscle growth
medium (SkGM2), skeletal muscle basal medium
(SkBM2), and fusion medium (Dulbecco modified Eagle
medium; F12, 1:1) required for HSMM and the AdipoRed
assay reagent required for adipocyte staining were obtained
from Lonza, Basel, Switzerland. Ninety-six–well white
plate required for fluorimetry reading (adipocyte staining)
and other tissue culture plastic wares were procured from
Nalgene, Rochester, NY. Tissue culture grade trypsin,
EDTA, dimethylsulfoxide, human insulin, HEPES, bovine
serum albumin (radioimmunoassay [RIA] grade), Bradford
reagent, chloroform, and sodium pyruvate buffer were
obtained from Sigma (St Louis, MO). Glucose, triglyceride
(TG), cholesterol, aspartate transaminase (AST), and
alanine transaminase (ALT) kits were procured from
DiaSys, Holzheim, Germany. Enzyme-linked immunosor-
bent assay kits for mouse insulin were obtained from Linco
Research, St. Charles, MO; and isoflurane was from
Piramal Health Care, Mumbai. 2-Deoxy-D-[3H] glucose
and 2-deoxy-D-[14C]-glucose were procured from Amer-
sham Biosciences. TRIzol, Oligo(dT), dNTPs, reverse
transcriptase, dithiothreitol, RNaseOUT, and 5× strand
buffer were procured from Invitrogen (Carlsbad, CA).
Primer3 software and Genome browser were used to design
all the oligonucleotide primers (Table 1) synthesized by
Sigma, Bangalore, India. RNeasy mini kit was from Qiagen
(Hilden, Germany). QuantiFast SYBR Green Master Mix
for real-time polymerase chain reaction (PCR) was
procured from Qiagen. All other chemicals were procured
from Sigma.
2.2. Cell culture
Subcutaneous preadipocyte and HSMM cells were
cultured and grown as per supplier's protocol. In brief, SQ
cells were grown in PM-1 in T75 culture flask. A total of 4 ×
104/cm2 SQ cells were plated in 24-well plate and in 96-well
white plate in PM-1. Preadipose SQ cells were fed with DM2
after confluence. Peroxisome proliferator activated
receptor–γ (PPARγ) agonist in DM2 was replaced by
rosiglitazone or 18F9 for 6 days. After the differentiation,
cells were maintained in AM1 until the day of experiment.
All the cells were replenished with the respective medium on
alternative days. On day 11, the rate of adipogenesis was
measured using fluorimetry. In the gene expression study,
cells were lysed in TRIzol for RNA extraction after 4 days of
treatment. For glucose uptake study in human SQ cells, they
were maintained in AM1 until day 17. For glucose uptake in
HSMM, cells were grown in SkGM2 in T75 culture flask; 4 ×
104/cm2 HSMM cells were plated in 24-well plate in
SkGM2. On subconfluence, differentiation was initiated by
the addition of fusion medium supplemented with 2% horse
serum for 5 days. More than 90% of cells were converted
Table 1
Primers and probes used for real-time PCR
Assay Forward primer Reverse primer Accession no.
Glut1 CCTATGGCCAAGGACACACT GGGCGAATCCTAAAATGGAG NM_011400
Glut4 GACGGACACTCCATCTGTTG CTCAAAGAAGGCCACAAAGC NM_009204
Glut12 CATCGCTGGCTTTTGTTGT TGGCACTAATTCTTCCTGGTG NM_178934
Hk2 CAAGATAAGAGAGAACCGTGGA GAAGGACACGTCACATTTCG NM_013820
Rab5a TGGAGACATCAGCTAAGACATCA GCTGTGCAGGCTCAGTAAGG NM_025887
Cap2 TGCACTAGACTGTGAGATCGTG ATCTCTGCAGGTTCGGTGAC NM_026056
Gys1 AAGGCCTTTCCAGACCACTT TTCCTCATCCTCACTCTGGTG NM_030678
Lcb1 GATAAGGGCATCGCATTGAC GCCTCCCTGATGGTGGAT NM_009269
Lcb2 TGGTGTAGTTGTGGTGGGATT ACTTTAGCTGCAGCAGATCC NM_011479
Fasn GCACCTATGGCGAGGACTT ATGGATGATGTTGATGATGGA NM_007988
Thiolase1 AATTCCTGCAGAGAAGGTGAA ATGGACACCACGCCGTAAG NM_130864
Thiolase2 GTCAGGCCGTCTACTGTGTG GGCGCTTCAGTTCATTGAGT NM_146230
Hmgcs2 AGACGCATGTCCCCTGAG TGCATCTCATCCACTCGTTC NM_008256
Dgat1 GTTCCCCTGCGGATGTTC ACCGGTTGCCCAATGATG NM_010046
CD36 TCTGAAGAGACCTTACATTGTACCTA CAATCCCAAGTAAGGCCATC NM_007643
Fabp3 GGACGGAGGCAAACTCATC ACGCCTCCTTCTCATAAGTCC NM_010174
Fabp4 ACGACAGGAAGGTGAAGAGC ACACATTCCACCACCAGCTT NM_024406
mCpt-1 CATGATCGCAGGAGAAAACA TCAGCTGTCTGTCTTGGAAA NM_009948
Acc2 ATCAATTATCTGAAGCGGGACT AGCAGCTGAGCCACCTGTAT NM_133904
Acox1 CTTTAAGGATGTGACCCTTGG GACTGCAGGGGCTTCAAGT NM_015729
Pdk4 GGAGATCTGAATCTCTACTCTATGTCA CAGCTTCGGAGCTCATCTG NM_013743
Adiponectin CAGGACATCCTGGCCACA CCCTTCAGCTCCTGTCATTC NM_009605
Ucp2 ACTGTGCCCTTACCATGCTC GCAGCCATTAGGGCTCTTTT NM_011671
Ucp3 CCTCTGCACTGTATGCTGAA ATTAAGGCCCTCTTCAGTTGC NM_009464
β-Tubulin GCACAATGGACTCAGTCAGG TCACCACGTCCAGGACAGA NM_001080971
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maintained in SkGM2 until the initiation of glucose uptake
study. Both SQ and HSMM cells were grown at 37°C
humidified with 5% CO2.
2.3. Animals
Female Wistar rats (6 weeks of age), male db/db and
C57BL/6J mice (7-9 weeks of age) were procured from the
central animal facility, Piramal Life Sciences Limited,
Mumbai. Animals were housed in individually ventilated
cages at a room temperature of 22°C ± 2°C, humidity at 55%±
5%, with a 12:12-hour light-dark cycle and throughout the
study period had access to water and standard chow ad
libitum. The guidelines of the Committee for the Purpose of
Control and Supervision of Experiments on Animals,
Government of India, were followed; and the in-house animal
ethics committee approved all experimental procedures.
2.4. Pharmacokinetic studies
Overnight-fasted (16 hours) db/db mice weighing 30 to
40 g were randomized into 4 groups (n = 4). 18F9 (30, 50,
and 100 mg/kg) or vehicle (0.5% carboxymethylcellulose
[CMC]) was administered orally, and 50 μL blood was
withdrawn from retroorbital sinus under isoflurane anesthe-
sia at different time intervals. Plasma was separated by
centrifugation at 6000g for 7 minutes at 4°C. Plasma level of
18F9 was determined by a high-performance liquid
chromatographic (HPLC) method developed in-house.
Briefly, the chromatographic system consisted of aThermo-Finnigan Surveyor LC pump with a photodiode
array detector (Thermo Electron, San Jose, CA). Compound
was separated at 40°C on a Thermo BDS Hypersil C18
column of 250 × 4.6 mm internal diameter and particle size
of 5 μm. The mobile phase composed of 2 solvents—solvent
a: 100% HPLC-grade acetonitrile; solvent B: 0.01 mol/L
ammonium acetate containing 0.5% vol/vol triethylamine,
pH adjusted to 2.5 with orthophosphoric acid. The mobile
phase was run at a flow rate of 1 mL/min using the following
gradient program (time [minutes]/percentage solvent A): 0/
20, 20/80, 20.01/20, and 25/20. Absorbance was measured at
312 nm. Unknown concentrations of 18F9 in the plasma
samples were determined using a calibration curve in mouse
plasma at concentrations ranging from 1 to 500 μg/mL. A
linear relationship for 18F9 (r2 = 0.999) was obtained when
peak areas were plotted against plasma concentration.
Coefficients of variation were always lower than 10%,
whereas accuracy ranged from 90% to 110%.
2.5. Biochemical estimation
Blood was collected from the retroorbital sinus of db/db
mice after 4-hour fasting under isoflurane anesthesia (3%
isoflurane anesthesia in O2 using anesthesia apparatus
[SurgiVet; Smiths Medical, Waukesha, WI]). Plasma was
separated by centrifugation at 6000g at 4°C for 7 minutes;
and glucose, TG, cholesterol, and liver enzymes AST and
ALT levels were estimated immediately using a biochemistry
autoanalyzer (Hitachi Science Systems Limited, Ibaraki,
Japan). Plasma insulin was estimated using enzyme-linked
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turer's protocol.3. Experiments
In all our experiments, rosiglitazone was used as a
standard insulin sensitizer for comparison.
3.1. Study 1: effect of 18F9 on adipogenesis in human
preadipose SQ cells
To measure the effect of 18F9 on accumulation of
intracellular TG (marker of adipocyte differentiation), we
performed Nile red–based staining [8]. Cultured preadipo-
cytes on confluence were induced to differentiate in the
presence of 18F9 (1, 10, and 100 μmol/L) and rosiglitazone
(1 μmol/L) in 96-well white plate. In an earlier study,
rosiglitazone caused dose-dependent adipogenesis with max-
imum effect at 1 μmol/L (data not shown). Therefore, we used
1 μmol/L of rosiglitazone for all of our adipogenesis studies.
After 11 days, cells were washed in phosphate-buffered saline
(PBS) at room temperature. Cells were then treated with 5 μL
of AdipoRed assay reagent in 200 μL of PBS per well and
incubated at room temperature for 10 minutes. After
incubation, fluorescence was measured using high-through-
put screening fluorimetry analyzer (Tecan-Safire, Durham,
NC) with excitation at 485 nm and emission at 572 nm.
3.2. Study 2: effect of 18F9 on adipogenic markers in
human preadipose SQ cells
To assess the gene expression profile of 18F9 in
adipogenesis, we tested its effect on differentiation of
human SQ preadipocytes. Cultured preadipocytes on con-
fluence were induced to differentiate in the presence of 18F9
(1, 10, and 100 μmol/L) and rosiglitazone (1 μmol/L). After
4 days of treatment, cells were washed with PBS and lysed in
TRIzol for RNA extraction. RNA was extracted from cell
lysate using RNeasy mini kit (Qiagen). Chloroform was
added to the cell lysate to separate out the protein, washed
with 70% alcohol, and then applied to RNeasy spin column;
and the subsequent steps were followed as per the supplier's
instruction. RNA was eluted in RNase/DNase free water
stored at −80°C in aliquots. The extracted total RNA was
run on a 3-(N-morpholino)propanesulfonic acid (MOPS)/
formaldehyde gel and quantified by using ND-1000 spectro-
photometer (Thermo Scientific NanoDrop, Wilmington,
DE). For complementary DNA (cDNA) conversion, 2 μg
of total RNA was treated with 50 μL Oligo(dT) and 10
mmol/L dNTPs and heated at 65°C for 5 minutes followed
by an ice incubation for 1 minutes. Total RNA was then
reverse transcribed to cDNA using 200 U of Superscript III
in the presence of 5× first-strand buffer, 0.1 mol/L
dithiothreitol, and 40 U of RNase inhibitor and incubated
at 50°C for 60 minutes followed by heat inactivation at 70°C
for 15 minutes. The list of primers used to amplify the
corresponding gene is shown in the Table 1. Real-time PCRwas carried out by the amplification of samples in 96-well
plates using Epgradient S, Realplex4 Mastercycler System,
and fluorescent dye SYBR green (Eppendorf, Hamburg,
Germany) following the manufacturer's protocol. Amplifi-
cation was carried out by initial denaturation at 95°C for 5
minutes followed by 40 cycles of 95°C for 10 seconds and
60°C for 30 seconds. All gene expressions were normalized
with β-tubulin, which served as an internal control to check
the quality of RNA. Data were analyzed using the Realplex
software (version 1.5, Eppendorf). The relative expression of
each gene was calculated using comparative Ct method with
the formula 2−ΔΔCt (where ΔΔCt = ΔCt sample − ΔCt
reference), where Ct is the number of cycles required to
reach the threshold.
3.3. Study 3: effect of 18F9 on glucose uptake in human
SQ cells
To evaluate the effect of 18F9 on glucose uptake in
human SQ cells, 2-deoxy-D-[14C]-glucose uptake was
measured. After differentiation, adipocytes were incubated
in AM1 until day 17. These cells were then maintained in
basal medium supplemented with 3% fetal calf serum for
another 3 days. Our preliminary studies revealed that
rosiglitazone caused a concentration-dependent (1, 10, and
100 μmol/L) stimulation of glucose uptake both in the
presence and in the absence of insulin. On day 20, cells were
incubated in the presence of rosiglitazone (100 μmol/L) or
18F9 (10 and 100 μmol/L) supplemented with 0.5% fetal
calf serum for 24 hours. Glucose uptake was initiated by
switching over the adipocytes to Krebs-Ringer phosphate
(KRPH) buffer (118 mmol/L NaCl, 4.8 mmol/L KCl, 1.3
mmol/L CaCl2, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4,
and 15 mmol/L HEPES). Cells were rinsed thoroughly in
KRPH buffer twice and incubated in KRPH buffer with or
without insulin (100 nmol/L) for 30 minutes. Afterward, the
glucose uptake was monitored in the presence of 0.2 μCi/mL
2-deoxy-D-[14C]-glucose (to the final concentration 100
μmol/L) for 30 minutes. The glucose uptake was terminated
rapidly by washing the cells in ice-cold KRPH buffer thrice,
and cells were lysed in 60 μL of 0.1% sodium dodecyl
sulfate. Cell lysate was used to measure the radioactivity
using liquid scintillation counter (Packard Biosciences,
Shelton, CT). Glucose uptake measurements were carried
out in triplicates.
3.4. Study 4: effect of 18F9 on glucose uptake in HSMM
Effect of 18F9 on glucose uptake in HSMM was
measured by 2-deoxy-D-[3H]-glucose uptake. After differ-
entiation, glucose uptake was initiated by switching over
the myotubes to SkBM2 (absence of nutrition factors). Our
initial findings demonstrated that insulin caused a dose-
dependent (0.01, 0.1, and 1 μmol/L) stimulation of glucose
uptake leading to a 2.0-fold increase over basal at the
maximum concentration. A similar dose-response study for
rosiglitazone (1, 10, and 100 μmol/L) in the presence and
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glucose uptake in HSMM cells. After the preincubation of
myotubes in 18F9 (10 and 100 μmol/L) and rosiglitazone
(100 μmol/L) in SkBM2 for 24 hours, cells were rinsed
thoroughly in KRPH buffer (150 mmol/L NaCl, 5 mmol/L
KCl, 1.2 mmol/L CaCl2, 1.2 mmol/L MgSO4, 2.5 mmol/L
NaH2PO4, and 10 mmol/L HEPES) twice and incubated in
KRPH buffer with or without insulin (1 μmol/L) for 1 hour.
Afterward, the glucose uptake was monitored in the
presence of 1.5 μCi/mL 2-deoxy-D-[3H]-glucose (final
concentration of 20 μmol/L deoxyglucose) for 15 minutes.
Glucose uptake was terminated rapidly by washing the cells
in ice-cold KRPH thrice, and cells were lysed in 60 μL of
0.1% sodium dodecyl sulfate. Cell lysate was used to
measure the radioactivity using liquid scintillation counter
(Packard). Glucose uptake measurements were carried out
in triplicates.
3.5. Study 5: dose-dependent effect of 18F9 on plasma
glucose and insulin in db/db mice
Male db/db mice were divided into 5 groups with similar
body weight and plasma glucose (mean ± SEM) and treated
with vehicle (0.5% CMC), rosiglitazone (5 mg/kg), or 18F9
(30, 50, and 100 mg/kg) orally twice a day for 10 days. On
day 10, 1 hour after the last dose, blood was collected from
the retroorbital sinus; plasma was separated; and biochem-
ical estimations were performed as described earlier.
3.6. Study 6: effect of 18F9 on biochemical parameters in
db/db and C57BL/6J mice
Male db/db and C57BL/6J mice were divided into 3
groups each with similar body weight and plasma glucose
(mean ± SEM). Mice were treated with 0.5% CMC,
rosiglitazone (5 mg/kg), or 18F9 (100 mg/kg) orally twice
a day for 10 days. One hour after the last dose, on day 10,
blood was collected from the retroorbital sinus; plasma was
separated; and biochemical estimations were performed as
described earlier. Immediately after blood sample collection,
mice were killed; and soleus muscle was excised for ex vivo
glucose uptake and gene expression study. From the same
mice, epididymal fat was collected for gene expression study.
3.7. Study 7: effect of 18F9 on plasma volume and heart
weight in normal rats
Plasma volume estimation was performed as described
previously [9] with slight modification. Briefly, female
Wistar rats were administered 18F9 (250 mg/kg) or
rosiglitazone (40 mg/kg) once daily for 28 days. In this
study, 18F9 was administered once daily in contrast to the
twice a day dosing regimen followed in the efficacy study in
mice because 18F9 demonstrated a longer elimination half-
life (t1/2) of 3.36 hours in rats as compared with a t1/2 of 0.74
hour in mice. On day 29, that is, after completing the 28-day
treatment, animals were anesthetized; the jugular vein andcarotid artery were catheterized for dye injection and sample
collection, respectively. Blood (0.5 mL) was collected for
obtaining baseline plasma samples. Afterward, 0.5 mL of
Evans blue solution in saline (2 mg/mL) was administered
intravenously through the jugular vein. Five minutes later,
0.5 mL of blood was collected to measure Evans blue
concentration in the plasma. Plasma Evans blue concentra-
tions were determined according to a standard curve
generated by a serial dilution of Evans blue saline solution
(2 mg/mL). Plasma volume was calculated using the dilution
factors of Evans blue.
3.8. Study 8: effect of 18F9 on glucose uptake in soleus
muscle (ex vivo)
In a separate study, intact soleus muscles were rapidly
dissected from mice continuously treated with rosiglitazone
(5 mg/kg, bid) and 18F9 (100 mg/kg, bid) for 10 days. Both
ends of soleus muscle were tied with suture and mounted on
the stainless steel clips to maintain consistent resting muscle
length and tension. The tissue was then incubated at 35°C for
30 minutes in a shaking incubator in 2 mL of oxygenated
Krebs-Henseleit buffer (KHB) (104 mmol/L NaCl,
4 mmol/L KCl, 1.1 mmol/L CaCl2, 1 mmol/L MgSO4, 1.2
mmol/L KH2PO4, 22 mmol/L NaHCO3, and 6.7 mmol/L
HEPES) supplemented with 8 mmol/L glucose, 32 mmol/L
mannitol, and 0.1% RIA-grade bovine serum albumin (BSA)
with or without insulin (100 nmol/L). All muscles were
rinsed at 29°C for 10 minutes in 2 mL of KHB containing 40
mmol/L mannitol and 0.1% BSA (RIA grade), with or
without 100 nmol/L insulin, to remove glucose from the
extracellular space. After rinsing, muscles were incubated at
29°C for 20 minutes in 1 mL of KHB containing 0.2 μCi/mL
2-deoxy-D-[14C]-glucose, 2 mmol/L sodium pyruvate, and
0.1% BSA, with or without recombinant human insulin (100
nmol/L). All incubations were performed in stoppered vials
gassed with 5% CO2 and 95% O2. Muscles were processed
by dissolving in 1 N NaOH at 65°C for 10 minutes and then
further neutralized with 1 N HCl. Finally, homogenate was
centrifuged at 2000g. An aliquot of the supernatant was
added to the scintillation cocktail, and the radioactivity was
measured. Furthermore, an aliquot was used for the protein
estimation (Bradford method); and the radioactivity counts
were normalized against total protein concentration, reported
as counts per minute per milligram of protein.
3.9. Study 9: PPARγ transactivation study with 18F9
Cell-based transcription assay was used to identify
PPARγ agonists as previously described [10,11]. CV-1
cells were maintained in modified Eagle medium containing
10% fetal bovine serum. Cells were seeded at a density of
80 000 cells per well in a 24-well plate 1 day before
transfection. CV-1 cells were transiently transfected with
expression vector (hPPAR-LBD fused to DBD of yeast
transcription factor GAL4) and reporter vector (GAL4
response element and a reporter gene that codes for firefly
Fig. 1. Effect of 18F9 on adipogenesis in human subcutaneous preadipose
cells. Confluent human subcutaneous fibroblasts were treated with 18F9 (1,
10, and 100 μmol/L) or rosiglitazone (1 μmol/L) for 6 days. Cells were
maintained in AM1 until day 11. On day 11, cells were rinsed with PBS and
stained with AdipoRed reagent; and fluorescence was measured with
excitation at 485 nm and emission at 572 nm. Fluorescence was represented
as relative fluorescence units. Data represent mean ± SEM (n = 3). ⁎⁎⁎P b
.001 vs vehicle group.
ig. 2. Gene expression profiling of 18F9 in human SQs. Confluent human
Qs were treated with 18F9 (1, 10, and 100 μmol/L) or rosiglitazone (1
mol/L). After 4 days of treatment, total RNA was isolated and reverse
anscribed; and RT-PCR was performed as described in the methodology.
ll transcripts were normalized against the housekeeping gene β-tubulin.
xpression level of FABP4 (A), CD36 (B), and adiponectin (C) mRNAwas
lotted as relative fold change vs basal expression. Data represent mean ±
EM (n = 3). ⁎P b .05, ⁎⁎P b .01, and ⁎⁎⁎P b .001 vs vehicle group; #P b .05
vs rosiglitazone group.
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Complementary DNA construct containing Renilla lucifer-
ase was used as a control to check the efficiency of
transfection. 18F9 (0.1-10 μmol/L) or the full PPARγ
agonist rosiglitazone (1 μmol/L) was added 5 hours after
transfection. Receptor activation by ligands leads to
activation of luciferase expression, which was measured
after 15 to 16 hours of incubation. The cells were washed
with PBS and lysed, and luciferase activity was measured in
a microplate luminometer. Luminescence measure based on
the luciferase expression was normalized and expressed in
terms of fold change relative to untreated cells.
3.10. Study 10: effect of 18F9 on gene expression profiling
in soleus muscle and epididymal fat
The tissue samples were transferred to TRIzol reagent and
homogenized using PRO homogenizer (PRO Scientific,
Oxford, CT). RNA extraction and cDNA conversion from
the tissue homogenate were performed as explained in study
2. The list of primers used to amplify the genes of interest is
summarized in Table 1.
3.11. Statistical analysis
All the results including the gene expression study data
are expressed as mean ± SEM. Statistical analysis was done
using GraphPad Prism 4 (version 4.03; GraphPad Software,
La Jolla, CA). Unpaired Student t test (2-tailed) was
performed for statistical analysis of differences while
comparing the mean values with respective group controls.
For analysis of data of in vivo efficacy study, 1-way analysis
of variance followed by Dunnett post hoc analysis was used.4. Results
4.1. Effect of 18F9 on adipogenesis and adipogenic markers
in human SQ cells
To investigate the effect of 18F9 and rosiglitazone on
adipogenesis, we performed fluorescence-based Nile red
staining (Fig. 1) and studied the gene expression profile of
key adipogenic markers (FABP4, CD36, and adiponectin)
by reverse transcriptase (RT)–PCR (Fig. 2). 18F9 enhanced
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with rosiglitazone (1 μmol/L). In addition, 18F9 exhibited
dose-dependent (1, 10, and 100 μmol/L) up-regulation of
the adipogenic markers. 18F9 and rosiglitazone demon-
strated a significant up-regulation of FABP4, CD36, and
adiponectin (Fig. 2A-C). Interestingly, 18F9 (100 μmol/L)
elicited 1.4-fold higher expression of adiponectin gene over
rosiglitazone (18F9 vs rosiglitazone: 11.2 ± 1.7 vs 8.4 ± 1.2,
P b .05, Fig. 2C).
4.2. Effect of 18F9 on glucose uptake in human
SQ adipocytes
The effect of 18F9 and rosiglitazone on glucose uptake in
human adipocytes was measured using 2-deoxy-D-[14C]-Fig. 3. Effect of 18F9 on glucose uptake in human subcutaneous adipocytes and h
with 18F9 (10 or 100 μmol/L), rosiglitazone (100 μmol/L), or 0.1% dimethylsulfoxi
insulin as described in the methodology. A, Glucose uptake in human SQ adipocyt
for 30 minutes. B, Glucose uptake in HSMM was monitored by the addition of 1.5
SEM (n = 3). Glucose uptake is expressed as counts per minute per well. @@@P b .0
.001 vs rosiglitazone basal uptake.glucose (Fig. 3A). Insulin stimulated glucose uptake by 1.5-
fold over basal uptake at 100 nmol/L. 18F9 did not increase
basal glucose uptake at both 10 and 100 μmol/L, but
rosiglitazone (100 μmol/L) caused a significant increase (2.0-
fold) in basal glucose uptake (Fig. 3A). Interestingly, 18F9 at
100 μmol/L increased insulin-mediated glucose uptake sig-
nificantly by 1.7-fold as compared with basal glucose uptake. In
contrast, rosiglitazone at 100 μmol/L showed insulin-mediated
glucose uptake by 1.3-fold over basal glucose uptake.
4.3. Effect of 18F9 on glucose uptake in HSMM
The effect of 18F9 and rosiglitazone on glucose uptake in
human myotubes was measured by 2-deoxy-D-[3H]-glucose
(Fig. 3B). Insulin stimulated glucose uptake by 2.0-fold overuman myotubes. Differentiated cells (human SQ or HSMM) were incubated
de (vehicle) for 24 hours. Afterward, the cells were incubated with or without
es was monitored by the addition of 0.2 μCi/mL of 2-deoxy-D-[14C]-glucose
μCi/mL of 2-deoxy-D-[3H]-glucose for 15 minutes. Data represent mean ±
01 and @@P b .01 vs control group; ⁎⁎⁎P b .001 vs 18F9 basal uptake; $$$P b
Fig. 5. Effect of 18F9 on plasma glucose and insulin in db/db mice. db/db
mice were treated for 10 days (twice a day) with vehicle, 18F9 (30, 50, and
100 mg/kg), or rosiglitazone (5 mg/kg). Plasma glucose (A) and insulin
(B) were measured after 10 days of treatment. Data represent mean ± SEM
(n = 8). ⁎⁎⁎P b .001 vs control group.
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modest stimulation of basal glucose uptake by 1.6-fold,
whereas rosiglitazone (100 μmol/L) caused a significant
increase in basal glucose uptake by 3.6-fold (Fig. 3B). 18F9
elicited a significant increase in insulin-mediated glucose
uptake by 1.7-fold as compared with basal glucose uptake.
On the other hand, rosiglitazone at 100 μmol/L showed
insulin-mediated glucose uptake by only 1.2-fold as
compared with basal glucose uptake.
4.4. Pharmacokinetic profile of 18F9
Fig. 4 shows the time-dependent plasma concentration
after oral administration of 30, 50, and 100 mg/kg of 18F9 in
overnight-fasted db/db mice. Plasma level of 18F9 reached a
maximum (Cmax) of 139, 397, and 748 μmol/L in 15 minutes
and decreased thereafter. Thus, the plasma concentrations
reached were significantly higher than those used for in vitro
studies. Furthermore, the t1/2 being 0.74 hour, a 100-mg/kg
(bid) dosing regimenwas followed for in vivo studies inmice.
4.5. Dose-dependent effect of 18F9 on plasma glucose and
insulin in db/db mice
The 18F9 and rosiglitazone groups exhibited a significant
reduction in plasma glucose as compared with the control
group (Fig. 5A). After 10 days of treatment, the 18F9 group
displayed a marked glucose reduction of 28%, 46%, and
57% at 30, 50, and 100 mg/kg, respectively, whereas
rosiglitazone at 5 mg/kg demonstrated a 44% reduction as
compared with the control group. Plasma insulin was
reduced in a dose-dependent manner in the 18F9-treated
group (Fig. 5B). At 100 mg/kg, 18F9 demonstrated a plasma
glucose and insulin reduction comparable with rosiglitazone,
clearly supporting its in vivo insulin-sensitizing activity.
4.6. Effect of 18F9 on biochemical parameters in db/db and
C57BL/6J mice
Table 2 shows the effect of 18F9 (100 mg/kg, po) and
rosiglitazone (5 mg/kg, po) twice-daily treatment on body
weight, liver weight, and other biochemical parameters in
C57BL/6J and db/db mice. Although the plasma TG level ofFig. 4. Pharmacokinetic profile of 18F9 in db/db mice. Overnight-fasted db/
dbmice were administered 30, 50, and 100 mg/kg of 18F9 orally. Blood was
drawn at periodic intervals, and plasma concentration of 18F9 was
determined by HPLC. Data represent mean ± SEM (n = 4).the 18F9-treated group was reduced as compared with that of
the control C57BL/6J mice, the effect was not reflected on
body weight. Rosiglitazone-treated C57BL/6J mice also did
not show change in biochemical parameters. However, in db/
db mice, 18F9 and rosiglitazone exhibited a significant
reduction in plasma insulin levels as compared with the
control group. Rosiglitazone induced a significant gain in
body weight as compared with the control group. Notably,
there was a small gain in weight of 18F9-treated mice, too;
but the same was significantly (P b .05) lesser when
compared with rosiglitazone group. Both 18F9 and rosigli-
tazone caused significant reduction of plasma TG in db/db
mice. Unlike rosiglitazone, 18F9 did not affect the plasma
cholesterol. Rosiglitazone caused a significant increase in
liver weight and liver toxicity marker enzymes ALTand AST
by 2.1- and 2.8-fold, respectively, over control group,
whereas 18F9 did not cause any change.
4.7. Effect of 18F9 on plasma volume and heart weight
The effect of 18F9 or rosiglitazone treatment on
cardiovascular parameters was assessed in a 28-day
Table 2
Effect of 18F9 (100 mg/kg, bid, po) or rosiglitazone (5 mg/kg, bid, po) on body weight, liver weight, and other biochemical parameters in C57BL/6J and db/db
mice
Parameter C57BL/6J db/db mice
Control Rosiglitazone 18F9 Control Rosiglitazone 18F9
Body weight (g) 24.9 ± 0.5 24.3 ± 0.4 23.7 ± 0.4 35.7 ± 1.9 42.3 ± 0.7⁎ 38.0 ± 0.8†
PGL (mg/dL) 187.8 ± 8.4 188.8 ± 9.3 195.5 ± 11.6 510.3 ± 24.1 286.1 ± 21.3⁎ 262.0 ± 19.8⁎
TG (mg/dL) 111.4 ± 14.3 142.8 ± 19.8 65.4 ± 2.7⁎ 102.4 ± 8.0 56.0 ± 3.9⁎ 66.4 ± 11.9⁎
CHL (mg/dL) 81.9 ± 6.4 100.8 ± 2.7 82.7 ± 8.4 107.7 ± 4.8 55.9 ± 3.0⁎ 111.4 ± 8.9
ALT (IU/L) 36.1 ± 5.3 59.3 ± 9.5 43.4 ± 7.5 25.1 ± 3.6 50.4 ± 5.0⁎ 21.4 ± 8.4
AST (IU/L) 99.5 ± 13.3 91.1 ± 14.5 82.8 ± 14.0 75.4 ± 10.6 208.0 ± 30.1⁎ 65.1 ± 29.1
Insulin (ng/mL) 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 8.3 ± 1.0 2.5 ± 0.6⁎ 2.0 ± 0.3⁎
Liver weight (g/kg body weight) 39.4 ± 2.0 40.4 ± 1.2 40.6 ± 3.7 56.6 ± 2.4 63.6 ± 2.1⁎ 52.6 ± 1.8
Data shown as mean ± SEM of n = 8. PGL indicates plasma glucose levels; TG, triglycerides; CHL, cholesterol; ALT, alanine transaminase; AST,
aspartate transaminase.
⁎ P b .05 vs control group.
† P b .05 vs rosiglitazone group.
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kg) treatment in rats produced a significant increase in
plasma volume and heart weight (Table 3). On the other
hand, 18F9 (250 mg/kg) did not cause any increase in
plasma volume or heart weight. Besides, unlike rosiglita-
zone, a 28-day treatment with 18F9 did not result in change
in body weight when compared with vehicle-treated group
(data not shown).
4.8. Effect of 18F9 on skeletal muscle glucose uptake
(ex vivo)
The effect of 18F9 (100 mg/kg, po, bid) and rosiglitazone
(5 mg/kg, po, bid) on ex vivo glucose uptake in soleus
muscle isolated from db/db mice was measured after 10 days
of treatment (Fig. 6). Interestingly, 18F9 had no effect on
basal glucose uptake but significantly increased insulin-
mediated glucose uptake (37%, P b .05). Conversely,
rosiglitazone increased both basal (38%) and insulin-
mediated glucose uptake (68%). 18F9- and rosiglitazone-
treated animals demonstrated 1.7- and 1.5-fold increase in
insulin-mediated glucose uptake over basal glucose uptake,
suggesting that plasma glucose reduction is partly due to
insulin sensitization in soleus muscle.Table 3
Effect of 18F9 (250 mg/kg, od, po) or rosiglitazone (40 mg/kg, od, po) on
plasma volume, body weight, heart weight, and biochemical parameters in
28-day study in rats
Parameters Control Rosiglitazone 18F9
Plasma volume (mL/kg) 29.0 ± 0.9 39.0 ± 1.4⁎ 29.8 ± 1.2
Body weight (% increase) 24.7 ± 2.8 38.6 ± 2.3⁎ 23.1 ± 1.0
Liver weight (g/kg body weight) 32.0 ± 1.5 35.3 ± 0.7 37.8 ± 1.3⁎
Heart weight (g/kg body weight) 3.0 ± 0.1 3.3 ± 0.1⁎ 3.0 ± 0.1
AST (IU/L) 70.2 ± 4.5 77.2 ± 11.7 72.0 ± 3.0
ALT (IU/L) 40.4 ± 2.6 41.6 ± 6.7 39.8 ± 3.3
Data shown as mean ± SEM of n = 8.
⁎ P b .05 vs control group.4.9. Effect of 18F9 on hPPARγ transactivation
To quantify PPARγ activation, we performed luciferase/
reporter-based hPPARγ transactivation assay in CV-1 cells.
Both 18F9 and rosiglitazone showed dose-dependent
stimulation of PPARγ activity as compared with basal
activity in vehicle-treated cells. Relatively, 18F9 has a weak
transactivation potential when compared with rosiglitazone.
At 10 μmol/L, rosiglitazone exhibited approximately 17-fold
PPARγ activation, whereas 18F9 showed approximately
7-fold activation over basal (Fig. 7).5. Gene expression profiling in soleus muscle
5.1. Glucose metabolism
Fig. 8A illustrates the effect of 18F9 on the modulation of
key genes involved in glucose homoeostasis. 18F9 up-
regulated Hk2 and Glut12 messenger RNA (mRNA),
whereas rosiglitazone did not show any effect on them,
when compared with the control group. Both 18F9 and
rosiglitazone up-regulated the genes involved in insulin-
mediated glucose uptake (Glut4 and Rab5a) and glucose
disposal (Gys1) when compared with the control group (Fig.
8A). Glut4, Glut12, and Gys1 were better up-regulated (P b
.05) by 18F9 over rosiglitazone (18F9 vs rosiglitazone:
Glut4, 2.4- vs 1.5-fold; Glut12, 1.8- vs 1.1-fold; Gys1, 2.3-
vs 1.3-fold). On the other hand, rosiglitazone demonstrated
significant increase in basal glucose transporter (Glut1),
whereas 18F9 caused a modest up-regulation (Glut1, 18F9
vs rosiglitazone, 1.4 vs 2.0).
5.2. Lipid absorption, de novo lipid synthesis,
and β-oxidation
Fig. 8B illustrates the expression of key genes
underlying the molecular basis of lipid absorption, lipid
synthesis, and lipid oxidation in soleus muscle after
treatment with 18F9. Both 18F9 and rosiglitazone
demonstrated their beneficial effects on intracellular lipid
Fig. 6. Effect of 18F9 on glucose uptake in soleus muscle of db/db mice. db/db mice were treated orally (twice a day) with vehicle, 18F9 (100 mg/kg), or
rosiglitazone (5 mg/kg). On day 10, 1 hour after the dose, mice were killed; and soleus muscle was excised and incubated for 30 minutes at 35°C in 2 mL KHB
buffer supplemented with 8 mmol/L glucose, 32 mmol/L mannitol, and 0.1% RIA-grade BSAwith and without 100 nmol/L insulin. All muscles were rinsed at
10-minute incubation at 29°C with 2 mL KHB containing 40 mmol/L mannitol and 0.1% BSA (RIA grade), with or without 100 nmol/L insulin, to remove
extracellular glucose. This was followed by incubation with 0.2 μCi/mL 2-deoxy-D-[14C]-glucose containing 2 mmol/L sodium pyruvate and 0.1% BSA, with or
without insulin 100 nmol/L, in 1 mL KHB at 29°C for 20 minutes. The tissues were homogenized and centrifuged, and radioactivity was measured using a
scintillation counter. Results were normalized as counts per minute per milligram of soleus muscle protein. Data represent mean ± SEM (n = 7). @P b .05 vs
control; ⁎P b .05 vs 18F9 basal uptake; $P b .05 vs rosiglitazone basal uptake.
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Cpt1 being selectively enhanced by 18F9 (Fig. 8B).
Transcripts of Lcb1 and Lcb2 involved in de novo fatty
acid synthesis were unchanged in either treatment group
(Fig. 8C), whereas Fasn was significantly up-regulated in
both treatment groups. Fig. 8D illustrates that rosiglita-
zone improved cholesterol synthesis and its esterification
through up-regulation of Thiolase1 and 2. The key
enzyme involved in the TG synthesis, Dgat1, was alsoFig. 7. Activation of PPARγ by 18F9 and rosiglitazone. Induction of PPARγ
mediated transactivation by 18F9 and rosiglitazone. CV-1 cells were
cotransfected transiently with PPARγ1 expression vector, Gal4-PPARγ1-
LBD, and pGL2 (Gal4 × 5)-SV40-Luc reporter construct. Transfected cells
were treated with increasing concentrations of 18F9 and rosiglitazone, as
mentioned in “Materials and methods.” Luminescence measured based on
the luciferase expression was normalized and expressed in terms of fold
change relative to untreated cells. Data represent mean ± SEM (n = 3).significantly elevated by 18F9 and rosiglitazone (Fig.
8C). Acc2 and Acox1 were also equally up-regulated by
18F9 and rosiglitazone as compared with control group
(Fig. 8E). Interestingly, 18F9, but not rosiglitazone,
elicited a significant up-regulation of Pdk4 as compared
with control group (18F9 vs rosiglitazone: 1.7- vs
0.8-fold, P b .01).
5.3. Thermogenesis
To analyze the role of 18F9 in energy expenditure, Ucp2
and Ucp3 gene expression was studied. Both 18F9 and
rosiglitazone caused a modest up-regulation of Ucp2 (Fig.
8F). Furthermore, 18F9 demonstrated a significant up-
regulation of Ucp3 when compared with control group.
Notably, in comparison with rosiglitazone, 18F9 showed a
significant (P b .05) up-regulation of Ucp3 (Fig. 8F).6. Gene expression profiling in epididymal fat
6.1. Adipogenic markers
The effect of 18F9 on the expression of adipogenic
markers (ie, Glut4, CD36, Fabp4, and adiponectin) in
epididymal fat is illustrated in Fig. 9A. CD36 and Fabp4
were equally up-regulated by 18F9 and rosiglitazone
treatment (Fig. 9A). Interestingly, transcripts level of Glut4
and adiponectin were markedly up-regulated by 18F9,
whereas rosiglitazone demonstrated a modest up-regulation
for the same (Fig. 9A).
Fig. 8. Gene expression profiling for 18F9 in soleus muscle in db/db mice. db/db mice were treated orally (twice a day) with 18F9 (100 mg/kg) or rosiglitazone
(5 mg/kg). One hour after the last dose on day 10, animals were killed; and soleus muscle was excised. Total RNAwas isolated and reverse transcribed, and RT-
PCR was performed as described in methodology. All transcripts were normalized against the housekeeping gene β-tubulin. Expression level of each gene was
plotted as relative fold change over basal expression. Relative expression of genes involved in glucose metabolism (A), lipid absorption (B), lipogenesis
(C), cholesterol synthesis and esterification (D), β-oxidation (E), and thermogenesis (F). Data represent mean ± SEM (n = 7). ⁎P b .05, ⁎⁎P b .01, and ⁎⁎⁎P b .001
vs control group; #P b .05, ##P b .01, and ###P b .001 vs rosiglitazone group.
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As 18F9 up-regulated thermogenic marker genes in
soleus muscle, it was of interest to examine the same in
epididymal fat (Fig. 9B). Ucp2 was significantly up-
regulated by both 18F9 and rosiglitazone. In addition,
Ucp3 was also significantly up-regulated in both treatments.
7. Discussion
A recent study demonstrated that 18F9 exhibited
enhanced adipogenesis and glucose uptake in 3T3-L1 cells,
indicating its potential insulin-sensitizing activity [4]. In the
present study, we further evaluated the insulin-sensitizing
activity of 18F9 using human adipocytes, myotubes, and
db/db mice. 18F9 enhanced insulin-mediated glucose uptake
in human SQ and HSMM cells. These findings prompted us
to explore the efficacy of 18F9 in vivo in db/db mice. Long-
term treatment of db/db mice with 18F9 lowered plasma
glucose and insulin level without significant gain in body
weight and liver weight and increase in liver enzyme.
Because skeletal muscle accounts for a major fraction ofglucose utilization, we further performed ex vivo–based
soleus muscle glucose uptake study in continuously treated
db/db mice. We found that 18F9 increased the insulin-
mediated glucose uptake, whereas it did not alter the basal
uptake in soleus muscle. To understand the molecular
mechanism, we assessed its hPPARγ transactivation poten-
tial in vitro and the gene expression profiling in epididymal
fat and soleus muscle of continuously treated db/db mice.
18F9 exhibited a weak PPARγ activity and increased
expression of genes involved in lipid synthesis, oxidation,
and thermogenesis at par with rosiglitazone. Interestingly,
18F9 enhanced marked up-regulation of mRNA of key
transporters of glucose uptake (Glut4 and Glut12), glucose
disposal (Gys1), fat fuel utilization (Pdk4), and adiponectin
expression when compared with rosiglitazone.
Although 18F9 has been reported to cause adipogenesis
in 3T3-L1 preadipocyte [4], its effect on human preadipocyte
is not known. Therefore, we studied the effect of 18F9 on
human SQ preadipocytes. 18F9 enhanced adipogenesis at
par with rosiglitazone at a concentration 100 times greater
than rosiglitazone, suggesting its weak adipogenic potential.
We found that 18F9 up-regulated the expression of FABP4,
Fig. 9. Gene expression profiling of 18F9 in epididymal fat in db/db mice.
db/db mice were treated orally (twice a day) with 18F9 (100 mg/kg) or
rosiglitazone (5 mg/kg). One hour after the last dose on day 10, animals were
killed; and epididymal fat was excised. Total RNAwas isolated and reverse
transcribed, and RT-PCR was performed as described in methodology. All
transcripts were normalized against the housekeeping gene β-tubulin.
Expression level of each gene was plotted as relative fold change against
basal expression. A and B, Relative expression of genes involved in
adipogenesis and thermogenesis. Data represent mean ± SEM (n = 7). ⁎P b
.05, ⁎⁎P b .01, and ⁎⁎⁎P b .001 vs control group.
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action. A similar increase in adipogenic markers was also
observed in epididymal fat of db/db mice treated with 18F9.
In this study, rosiglitazone also enhanced adipogenesis and
expression of all key adipogenic markers, which is in line
with similar findings using TZDs in 3T3-L1 preadipocytes
[12,13]. Thiazolidinediones have been reported to cause an
increase in basal glucose uptake in 3T3-L1 adipocytes and
human myotubes [4,14,15]. In agreement with these reports,
rosiglitazone in our study predominantly increased basal
glucose uptake in both human SQ and HSMM cells. Unlike
rosiglitazone, 18F9 increased insulin-mediated glucose
uptake in human SQ but did not alter the basal glucose
uptake. On the other hand, 18F9 demonstrated a slight
increase in basal uptake while showing a marked increase in
insulin-mediated glucose uptake in HSMM cells.
Long-term treatment with 18F9 resulted in a dose-
dependent lowering of plasma glucose and insulin levels in
db/db mice. 18F9 was as effective as rosiglitazone in
reducing plasma glucose and insulin. However, 18F9
showed efficacy equivalent to rosiglitazone (5 mg/kg, bid)
at 20 times higher dose (ie, at 100 mg/kg, bid). Nevertheless,
the reduction in glucose in both treatment groups correlated
well with decreased insulin level, suggesting the in vivo
insulin-sensitizing activity. Compounds with weak PPARγactivity have demonstrated potent insulin sensitization
[16,17]. Interestingly, our observation on 18F9 corroborates
that a weak PPARγ activation is sufficient for insulin
sensitivity. In addition, a less potent adipogenic activity in
vitro, nonsignificant body weight gain, and no plasma
volume expansion by 18F9 could be due to its weak PPARγ
activity. Unlike rosiglitazone, 18F9 did not show reduction
in plasma cholesterol levels.
Considering the fact that 18F9 caused insulin sensitiza-
tion in vivo and increased insulin-mediated glucose uptake in
HSMM, we thought it will be worth examining ex vivo
glucose uptake in soleus muscle of continuously treated db/
db mice. We found that rosiglitazone enhanced both basal
and insulin-mediated glucose uptake, whereas 18F9
enhanced insulin-mediated glucose uptake only, which is
in agreement with our in vitro findings.
To elucidate the mechanism, we performed gene expres-
sion profile in soleus muscle and epididymal fat of db/db
mice continuously treated with 18F9 and rosiglitazone.
Expression of insulin-responsive glucose transporters Glut4
and Glut12 was predominantly elevated by 18F9, whereas
Glut1 mRNA, the glucose transporter mediating basal
glucose uptake, was markedly up-regulated by rosiglitazone.
These findings substantiate the in vitro– and ex vivo–based
glucose uptake observed with 18F9 on comparison with
rosiglitazone. Earlier reports indicated that rosiglitazone
improved peripheral glucose utilization in Zucker fatty rats
by elevating Glut1 in adipose tissue and in skeletal muscle
[18]. Given the fact that 18F9 preferentially elevated Glut4
and Glut12 mRNA in addition to increased insulin-mediated
glucose uptake in soleus muscle, human SQ, and HSMM
cells, it is likely that 18F9 is a promising insulin sensitizer.
Rab5a, a key regulator of phosphoinositide 3-kinase–
mediated glucose uptake [19], was up-regulated by 18F9 and
rosiglitazone. Interestingly, 18F9 seems to better regulate
nonoxidative glucose disposal through up-regulation of
Gys1 as compared with rosiglitazone. A previous study has
depicted that impaired glycogen synthesis is one of the major
causative factors for insulin resistance [20]. Therefore, we
conclude that the direct activation of phosphoinositide 3-
kinase–dependent glucose uptake by 18F9 may result in the
enhanced insulin sensitivity observed in the continuously
treated db/db mice.
A recent report demonstrated that pioglitazone (TZD)
treatment increases expression of Fasn and Dgat1 in human,
mice, and cultured 3T3-F442A preadipocytes [21]. Our
results extend these observations to skeletal muscle as well,
where both rosiglitazone and 18F9 up-regulated Fasn and
Dgat1. Besides, 18F9 also significantly up-regulated the
genes involved in fatty acid transport and oxidation (viz,
Fabp4, CD36, and Cpt1, and Acc2 and Acox1, respectively)
at par with rosiglitazone. Notably, unlike rosiglitazone, 18F9
significantly enhanced Pdk4 expression, which monitors the
preference of fuel utilization, that is, lipid oxidation over
glucose oxidation in diseased condition [22]. This elevation
of genes involved in lipid homeostasis suggests that 18F9
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transport, synthesis, as well as preferred utilization of fat as a
fuel source.
In the present study, 18F9 exhibited modest up-regulation
of Ucp2 in soleus muscle, whereas Ucp3 was significantly
up-regulated in both soleus muscle and epididymal fat. Ucp2
and Ucp3, the predominant uncoupling genes, regulate
energy expenditure and whole-body weight homeostasis by
regulating reactive oxygen species, ATP synthesis, and fatty
acid oxidation in mitochondria [23-25]. Interestingly, excess
lipid infusion over normal diet in rat leads to the activation of
CD36 along with a concomitant increase of Ucp2 and Ucp3,
implicating the role of uncoupling proteins in lipid oxidation
[26]. Emilsson and associates [27] indicated that enhanced
Ucp2 and Ucp3 expression in white adipose tissue could
result in thermogenesis in Zucker fa/fa rats with the
treatment of a β3-adrenoceptor agonist (BRL 35135).
Therefore, 18F9 may increase energy expenditure by
enhancing Ucp2 and Ucp3 expression in adipose tissue
and soleus muscle.
Our results demonstrated up-regulation of adiponectin
expression by 18F9 in human SQ cells and in epididymal fat
of continuously treated mice. Interestingly, adiponectin
promotes adipocyte differentiation, lipid accumulation, and
insulin sensitivity in 3T3-L1 cells [28], in addition to glucose
uptake in skeletal muscle [29,30]. A recent hyperinsulinemic
clamp study also demonstrated a positive correlation
between adiponectin and glucose disposal by nonoxidative
glucose disposal/glycogen synthesis [31]. Adiponectin plays
a major role in alleviating insulin resistance by the activation
of fatty acid transporters CD36 and Cpt1 [32,33]. A recent
report provides the physiologic mechanism by which Ucp2
controls adiponectin gene expression to increase systemic
insulin sensitivity [23]. Classic study of apelin on C57BL/6
mice demonstrated an increase in serum adiponectin with a
concomitant lowering of plasma insulin and TG and an
increased thermogenesis by the direct activation of Ucp3
[34]. Given the fact that 18F9 exhibited up-regulation of
genes involved in glucose disposal, lipid homoeostasis, fat
fuel utilization, and thermogenesis in association with up-
regulation of adiponectin mRNA, it is reasonable to assume
that adiponectin might play a significant role in 18F9-
mediated insulin sensitization.
In summary, 18F9 treatment caused adipogenesis in
human preadipocytes and enhanced glucose uptake in human
adipocytes, myotubes, as well as diabetic soleus muscle,
indicating its insulin-sensitizing activity. Long-term treat-
ment of 18F9 demonstrated equiantidiabetic activity when
compared with rosiglitazone but was devoid of hepatic
adverse effect, body weight gain in db/db mice, and plasma
volume expansion in rats. Although all the beneficial effects
of 18F9, both in vitro and in vivo, are observed at
concentration/dose higher than that of rosiglitazone, a
weak PPARγ activity may be responsible for this profile.
However, with the differential regulation of Pdk4 and the
better up-regulation of adiponectin mRNA and Ucp3 by18F9 when compared with rosiglitazone, the possibility of
other mechanisms cannot be ruled out. A structure search in
“Prous Integrity”(www.integrity.prous.com) revealed that
compounds with 80% structural similarity to 18F9 have
PTP1B inhibitory activity. Therefore, it is likely that PTP1B-
mediated mechanism might play a role in 18F9-mediated
insulin sensitization. Nevertheless, additional studies are
needed to elucidate the precise molecular mechanism.
Taking together the antidiabetic activity, hepatic and
cardiovascular safety profile, as well as enhanced glucose
uptake in human cells (adipose and skeletal muscle), it may
be worth developing 18F9 for the treatment of type 2
diabetes mellitus.
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